Lucid Diagnostics Announces First Commercial Insurance Coverage for EsoGuard® Esophageal DNA Test
NEW YORK, March 13, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. (Nasdaq: PAVM), has secured its first positive commercial insurance coverage policy. Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, will cover non-invasive screening for esophageal precancer and cancer using Lucid’s EsoGuard® Esophageal DNA Test. This coverage extends to patients meeting established criteria for esophageal precancer testing, as defined by professional society guidelines, within the state of New York.
This milestone represents a significant achievement for Lucid Diagnostics.
According to Dr. Lishan Aklog, Chairman and CEO of Lucid, this development validates their clinical evidence base.
“This positive policy coverage decision by a commercial insurer is a landmark event for Lucid. We believe that this decision will serve as a precedent to drive positive policy coverage decisions from other commercial insurers and further validates the strength of our clinical evidence base. We remain deeply engaged with commercial insurers across the country as we seek to expand access to EsoGuard precancer testing.”
This coverage decision is expected to serve as a precedent for other commercial insurers, potentially expanding access to the EsoGuard test.
Lucid Diagnostics is focused on individuals with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. The EsoGuard® Esophageal DNA Test, performed on samples collected via the EsoCheck® Esophageal Cell Collection Device, offers a noninvasive method for early detection to help prevent cancer and cancer deaths.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
